Suchergebnisse - "Xiang, Yan-Jun"

PubPharm (35)

1

Adjuvant sintilimab in resected high-risk hepatocellular carcinoma : a randomized, controlled, phase 2 trial

enthalten in: Nature medicine | 2024

von Wang, K. | Xiang, Y. | Yu, H. | +17

2

Discovery of distinct cancer cachexia phenotypes using an unsupervised machine-learning algorithm

enthalten in: Nutrition (Burbank, Los Angeles County, Calif.) | 2024

von Wu, H. | Yan, J. | Wu, Q. | +13

3

XAF1 promotes colorectal cancer metastasis via VCP-RNF114-JUP axis

enthalten in: The Journal of cell biology | 2024

von Xia, J. | Ma, N. | Shi, Q. | +21

4

Overall survival of patients with hepatocellular carcinoma treated with sintilimab and disease outcome after treatment discontinuation

enthalten in: BMC cancer | 2023

von Wang, K. | Xiang, Y. | Yu, H. | +7

5

Overall survival of patients with hepatocellular carcinoma treated with sintilimab and disease outcome after treatment discontinuation

enthalten in: BMC cancer | 2023

von Wang, K. | Xiang, Y. | Yu, H. | +7

6

Laparoscopic and open liver resection for hepatocellular carcinoma with type 2 diabetes mellitus : multicenter propensity score-matched study

enthalten in: Hepatology international | 2023

von Yang, S. | Feng, J. | Yan, M. | +11

7

Combination of alpha-fetoprotein and neutrophil-to-lymphocyte ratio to predict treatment response and survival outcomes of patients with unresectable hepatocellular carcinoma treated with immune checkpoint inhibitors

enthalten in: BMC cancer | 2023

von Zhu, H. | Feng, J. | Xiang, Y. | +7

8

Combination of alpha-fetoprotein and neutrophil-to-lymphocyte ratio to predict treatment response and survival outcomes of patients with unresectable hepatocellular carcinoma treated with immune checkpoint inhibitors

enthalten in: BMC cancer | 2023

von Zhu, H. | Feng, J. | Xiang, Y. | +7

9

Combination of alpha-fetoprotein and neutrophil-to-lymphocyte ratio to predict treatment response and survival outcomes of patients with unresectable hepatocellular carcinoma treated with immune checkpoint inhibitors

enthalten in: BMC cancer | 2023

von Zhu, H. | Feng, J. | Xiang, Y. | +7

10

A reasonable identification of the early recurrence time based on microvascular invasion for hepatocellular carcinoma after R0 resection : A multicenter retrospective study

enthalten in: Cancer medicine | 2023

von Liu, Z. | Chai, Z. | Feng, J. | +7